Product Description
CSK (C-terminal Src kinase), also known as CSK, is a member of the non-receptor tyrosine kinase family that plays a pivotal role in the negative regulation of Src family kinases (SFKs), thereby controlling cell proliferation, adhesion, migration, and immune responses. CSK phosphorylates a conserved C-terminal tyrosine residue (Tyr527 in Src) within SFKs, promoting an intramolecular interaction that locks these kinases in an inactive conformation. Beyond its essential physiological functions in maintaining cellular homeostasis and immune regulation, dysregulation of CSK signaling—including loss of function, reduced expression, or impaired activity—is closely associated with various human cancers (such as colorectal cancer, breast cancer, and glioblastoma), autoimmune diseases, and inflammatory disorders, making it a highly validated target for cancer therapy and drug discovery.
Screeningbio’s CSK Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying CSK kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: CSK catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the CSK kinase.
Data